Lubiprostone

🧮 Dose calculator

Chronic idiopathic constipation · Regimen source: FDA Amitiza · 2.1, Table 1

• • Moderate hepatic impairment: 16 mcg twice daily; severe: 8 mcg twice daily. Swallow whole. FDA Amitiza · 2.1, Table 1FDA Amitiza · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Amitiza · 8.1

  “Risk Summary Following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, M3, has measurable systemic concentrations [see Clinical Pharmacology (12.3) ] .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Amitiza · 8.2

  “Risk Summary There are no data available on the presence of lubiprostone in human milk or the effect of lubiprostone on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Amitiza · 8.4

  “Safety and effectiveness have not been established in pediatric patients with IBS-C, pediatric functional constipation (PFC), and OIC.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Amitiza · 8.5

  “Chronic Idiopathic Constipation The efficacy of Amitiza 24 mcg twice daily in the elderly (at least 65 years of age) subpopulation with CIC was consistent with the efficacy in the overall study population.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.